PSIC
The Pharmaceutical Sciences Industrial Corporation (PSIC) is a subsidiary of Alarfaj Medical Services Group, a company with over 45 years of experience in the medical field, PSIC is driven by a strong commitment to becoming a pioneer in the pharmaceutical biotechnology industry within Saudi Arabia and the Gulf Council Countries, we focus on advancing the development of specialized pharmaceuticals and vaccines that harness innovative liposomal nanotechnology.
As a company rooted in excellence, PSIC is dedicated to transfer cutting-edge pharmaceutical technology to preserve National Drug Security. Thus, promoting the Kingdom of Saudi Arabia’s role in the global pharmaceutical industry by localizing liposomal drug and vaccine industry in Saudi Arabia.
Our Vision
Our vision aligns with Saudi Vision 2030, which emphasizes innovation, economic diversity, and the transfer of advanced biotechnology into Saudi Arabia, PSIC is committed to being a catalyst for change, contributing to the evolution of the Kingdom’s pharmaceutical landscape by introducing superior global biotechnology, specifically in the production of life-saving drugs and vaccines that produced by un yet reach technology in Saudi pharmaceutical industry.
Our Mission
Our main target at PSIC is to be one of the leading pharmaceutical manufacturers in Saudi Arabia and the Middle East, focusing on specialized drugs and vaccines that utilize liposomal nanotechnology. In addition, PSIC will be the first company in the region to establish a transformative lipids industry, supplying three essential sectors: pharmaceuticals, food, and cosmetics, our mission is to support the kingdom and the region’s growing of these fundamental industries while fostering innovation and promoting sustainable growth.
Values and Principles
Our company is built on the principles of excellence, innovation, and community well-being, at PSIC We believe in contributing positively to the world around us, and that drives everything we do, from our internal processes to the products we deliver, we also hold ourselves accountable to the highest ethical standards, respecting our employees, partners, and customers.
Commitment to Quality
PSIC is committed to maintaining good manufacturing practices (GMP) and ensuring that all products meet required international industry standards, our adherence to quality control protocols is rigorous and is one of the cornerstones of our operations.
PSIC
Core Values
- Innovation:
By adopting cutting-edge technologies, like nanotechnology, to deliver advanced pharmaceutical solutions. - Quality:
“Quality is non-negotiable” That’s our motto, we always try to strive for excellence in every product we create & ensure safety and efficacy for our consumers. - Integrity:
Maintaining the highest ethical standards in all our business practices and ensuring transparency and accountability. - Collaboration: By working closely with global and local partners, we ensure the best possible outcomes for the healthcare industry in Saudi Arabia and beyond.
- Sustainability: Our commitment to sustainability extends through localizing these vital and essential technologies for manufacturing our products, which supports the Kingdom’s pharmaceutical security by aligning with international scientific progress to serves Saudi citizen by providing him all possible capabilities.
PSIC
Company Future
Looking ahead, PSIC is dedicated to expanding its footprint in the pharmaceutical biotechnology sector, we are actively pursuing research and development opportunities that will enable us to remain at the forefront of innovation, our long-term goal is to continually contribute to Saudi Arabia’s healthcare system and establish a global presence in the biopharmaceutical industry.
The Pharmaceutical Sciences Industrial Corporation (PSIC)
The Pharmaceutical Sciences Industrial Corporation (PSIC)
The Pharmaceutical Sciences Industrial Corporation (PSIC)
The Pharmaceutical Sciences Industrial Corporation (PSIC)
The Pharmaceutical Sciences Industrial Corporation (PSIC)
The Pharmaceutical Sciences Industrial Corporation (PSIC)
Team
Over 40 Years of Excellence in Saudi Arabia's Medical Services Sector
Sheikh Ibrahim Al-Oufaj: A Pioneer in the Healthcare Sector in Saudi Arabia
A visionary leader whose over 40 years of experience have shaped him into a prominent figure in Saudi Arabia's medical services industry. As the founder of Arfaj Medical Services Co., established in 1980, Sheikh Ibrahim has driven the company to achieve major milestones, solidifying its position as a leader in the Saudi market. His strategic vision, centred around delivering high-quality, efficient, and innovative healthcare solutions, has been the foundation of the company's success.
Sheikh Ibrahim Al-Oufaj: A Pioneer in the Healthcare Sector in Saudi Arabia
A visionary leader whose over 40 years of experience have shaped him into a prominent figure in Saudi Arabia's medical services industry. As the founder of Arfaj Medical Services Co., established in 1980, Sheikh Ibrahim has driven the company to achieve major milestones, solidifying its position as a leader in the Saudi market. His strategic vision, centred around delivering high-quality, efficient, and innovative healthcare solutions, has been the foundation of the company's success.
A Legacy of Quality, Growth, and Trust
Sheikh Ibrahim's commitment to excellence has fueled the company's growth and expanded its scope of operations. Under his leadership, Arfaj Medical Services has diversified into various sectors, including medical equipment trade, maintenance of medical devices, and contracting. This diversification has significantly broadened the company's reach, helping it to build a trusted reputation among its growing customer base.
His vision has been instrumental in the company's expansion into major investment projects, as well as its increasing classification as a contractor across multiple professional fields. Sheikh Ibrahim's relentless focus on quality and innovation has helped the company thrive and remain a trusted leader in the healthcare sector.
Shiek Ibrahim Abdulaziz AL Arfaj
Chairman
• 28+ years of experiences in drug and vaccine research, medical laboratories, and academia
• Co-supervised many postgraduate and undergraduate students in the fields of pharmaceutical, biochemistry and microbiology
• Currently a research scientist of nanomedicine at King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences (KSAUHS), and National Guard Health Affairs (NGHA); consultant in biomolecular sciences; a member of several scientific committees; and has published his work in peer-reviewed publications in the fields of drug discovery and drug nanotechnology
• Previously headed the Nanomedicine department at KAIMRC, KSAUHS, and NGHA
• Previously worked as Assistant Director for Planning & Development at Jeddah Poison Control Center
• Filed several patents in US Patents and Trademark Office and Saudi Patent Office
• Granted first patent on liposomal doxorubicin from US Patents and Trademark Office under registration number
• (US 9,655,847 Bl) in 2017, the global liposomal doxorubicin market size is estimated at $1.08 billion in 2020
• PhD and Masters in Biomolecular Sciences (Drug & Vaccine Delivery Systems) from Laurentian University, Sudbury, Canad
• Co-supervised many postgraduate and undergraduate students in the fields of pharmaceutical, biochemistry and microbiology
• Currently a research scientist of nanomedicine at King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences (KSAUHS), and National Guard Health Affairs (NGHA); consultant in biomolecular sciences; a member of several scientific committees; and has published his work in peer-reviewed publications in the fields of drug discovery and drug nanotechnology
• Previously headed the Nanomedicine department at KAIMRC, KSAUHS, and NGHA
• Previously worked as Assistant Director for Planning & Development at Jeddah Poison Control Center
• Filed several patents in US Patents and Trademark Office and Saudi Patent Office
• Granted first patent on liposomal doxorubicin from US Patents and Trademark Office under registration number
• (US 9,655,847 Bl) in 2017, the global liposomal doxorubicin market size is estimated at $1.08 billion in 2020
• PhD and Masters in Biomolecular Sciences (Drug & Vaccine Delivery Systems) from Laurentian University, Sudbury, Canad
Dr. Majed Abdulaziz Halwani
CO-Founder
Current Role:
Chairman, Community Health Sciences, College of Applied Medical Sciences, King Saud University.
Chairman, Saudi Health Promotion and Education Association.
Education:
PhD, Health Education (University of Nebraska-Lincoln).
MSc, Biostatistics (University of Nebraska-Lincoln).
Master of Health Education (University of Florida).
BSc, Health Care Management (Florida A&M University).
Chairman, Community Health Sciences, College of Applied Medical Sciences, King Saud University.
Chairman, Saudi Health Promotion and Education Association.
Education:
PhD, Health Education (University of Nebraska-Lincoln).
MSc, Biostatistics (University of Nebraska-Lincoln).
Master of Health Education (University of Florida).
BSc, Health Care Management (Florida A&M University).
Leadership & Administration:
Extensive experience in various leadership roles at King Saud University and the Ministry of Health.
Research & Publications:
40+ publications in peer-reviewed journals. Expertise encompasses diabetes management, cancer care, health literacy, and public health.
Successful grant acquisition for multiple research projects.
Teaching Experience:
Epidemiology, Health Statistics, Medical Sociology, Health Environmental Science, Demography, Health Insurance and Quality Control.
Key Skills & Expertise:
Biostatistics and data analysis (SPSS)
Health program evaluation and curriculum development
Public health research and advocacy
Professional Memberships:
Auditor, American Society for Public Health
Member, Behavioral Health
Member, Health Informatics Society
Member, World Health Organization (WHO)
Chairman, Saudi Health Promotion and Education Association
